Literature DB >> 16205971

Detection of Candida dubliniensis in Venezuela.

Claudia Hartung de Capriles1, Sofía Mata-Essayag, Celina Pérez, Maria Teresa Colella, Arantza Roselló, Carolina Olaizola, Sylvia Magaldi Teresa Abate.   

Abstract

Over the past decades there has been a significant increase in fungal infections caused by Candida species, and continues to be common in immunocompromised individuals infected with the human immunodeficiency virus (HIV). Although Candida albicans remains the fungal species most frequently isolated as an opportunistic oral pathogen, other non-albicans are often identified in this cohort of patients, including C. dubliniensis. This yeast is closely related to and shares many phenotypic characteristics with C. albicans. Colonies of these two species appear morphologically identical when not grown on special media. The shared phenotypic characteristics of C. dubliniensis and C. albicans suggest that many C. dubliniensis isolates may have been misidentified as C. albicans in the past. The present studies aim is to recover and identify C. dubliniensis, and presumptive clinical C. albicans, from the oral cavities of HIV-seropositive individuals, comparing conventional media to obtain a simple, low-cost and reliable identification system for C. dubliniensis. A total of 16 isolates (3,98%) had been obtained from 402 HIV infected individuals with recurrent oropharyngitis and were identified as C. dubliniensis. Out of these C. dubliniensis isolates 19% were resistant, with MICs above 64 microg/ml to fluconazole. This constitutes, to the authors knowledge the first recovery of this organism in Venezuela.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16205971     DOI: 10.1007/s11046-005-6873-y

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  38 in total

Review 1.  The ins and outs of DNA fingerprinting the infectious fungi.

Authors:  D R Soll
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

2.  Retrospective identification and characterization of Candida dubliniensis isolates among Candida albicans clinical laboratory isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected individuals.

Authors:  M A Jabra-Rizk; W A Falkler; W G Merz; A A Baqui; J I Kelley; T F Meiller
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

3.  Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

4.  Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998.

Authors:  M A Pfaller; R N Jones; G V Doern; H S Sader; S A Messer; A Houston; S Coffman; R J Hollis
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

5.  Molecular epidemiology of Candida albicans strains isolated from the oropharynx of HIV-positive patients at successive clinic visits.

Authors:  B A Lasker; C M Elie; T J Lott; A Espinel-Ingroff; L Gallagher; R J Kuykendall; M E Kellum; W R Pruitt; D W Warnock; D Rimland; M M McNeil; E Reiss
Journal:  Med Mycol       Date:  2001-08       Impact factor: 4.076

6.  Epidemiology of nosocomial fungal infections.

Authors:  S K Fridkin; W R Jarvis
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

7.  Prevalence of Candida dubliniensis isolates in a yeast stock collection.

Authors:  F C Odds; L Van Nuffel; G Dams
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

8.  International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe).

Authors:  M A Pfaller; R N Jones; G V Doern; A C Fluit; J Verhoef; H S Sader; S A Messer; A Houston; S Coffman; R J Hollis
Journal:  Diagn Microbiol Infect Dis       Date:  1999-09       Impact factor: 2.803

Review 9.  Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.

Authors:  V Krcmery; A J Barnes
Journal:  J Hosp Infect       Date:  2002-04       Impact factor: 3.926

Review 10.  Drug resistance in yeasts--an emerging scenario.

Authors:  Rajendra Prasad; Sneh Lata Panwar
Journal:  Adv Microb Physiol       Date:  2002       Impact factor: 3.517

View more
  5 in total

Review 1.  Candida dubliniensis: epidemiology and phenotypic methods for identification.

Authors:  Erico Silva Loreto; Liliane A Scheid; Cristina W Nogueira; Gilson Zeni; Janio M Santurio; Sydney H Alves
Journal:  Mycopathologia       Date:  2010-02-21       Impact factor: 2.574

2.  Antifungal Resistance of Candida Species Isolated from HIV Patients in a Tertiary Care Hospital, Mysuru, Karnataka.

Authors:  Umamaheshwari Shivaswamy; M N Sumana
Journal:  Indian J Dermatol       Date:  2020 Sep-Oct       Impact factor: 1.494

3.  Isolation of Candida dubliniensis for the first time in Cali, Colombia, and its identification with phenotyping methods.

Authors:  María Inés Alvarez; Blanca Lynne Suárez; Luz Dary Caicedo
Journal:  Mycopathologia       Date:  2008-07-12       Impact factor: 2.574

4.  Frequent detection of 'azole' resistant Candida species among late presenting AIDS patients in northwest Ethiopia.

Authors:  Andargachew Mulu; Afework Kassu; Belay Anagaw; Beyene Moges; Aschalew Gelaw; Martha Alemayehu; Yeshambel Belyhun; Fantahun Biadglegne; Zewdu Hurissa; Feleke Moges; Emiko Isogai
Journal:  BMC Infect Dis       Date:  2013-02-12       Impact factor: 3.090

5.  Species distribution and in vitro antifungal susceptibility of oral yeast isolates from Tanzanian HIV-infected patients with primary and recurrent oropharyngeal candidiasis.

Authors:  Omar J M Hamza; Mecky I N Matee; Mainen J Moshi; Elison N M Simon; Ferdinand Mugusi; Frans H M Mikx; Wim H van Palenstein Helderman; Antonius J M M Rijs; André J A M van der Ven; Paul E Verweij
Journal:  BMC Microbiol       Date:  2008-08-12       Impact factor: 3.605

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.